Reduction of Pain, Fatigue, Gastrointestinal and Other Symptoms and Improvement in Quality of Life Indicators in Fibromyalgia Patients with Membrane Lipid Replacement Glycerolphospholipids and Controlled-Release Caffeine

摘要

Objectives: A preliminary, open label study was initiated to determine if oral wafers containing a combination of membrane glycerolphospholipids and controlled-release caffeine could reduce self-reported pain, fatigue, and gastrointestinal symptoms and improve quality of life (QOL) indicators in fibromyalgia patients. Methods: Pain, fatigue and other symptoms were determined using validated, patient survey forms completed over an 8-day test period and compared to baseline values. Participants included 21 patients (15 females and 6 males) of average age of 48.5 ± 9.8 years with a diagnosis of fibromyalgia. These patients consumed four daily chewable wafers containing glycerolphospholipids (4.8 g) and one controlled-released caffeine (184 mg) wafer that maintained caffeine levels at approximately one cup of coffee for over 8 h. Results: Participants in the study responded to the combination test supplement within days. By the end of the study there were significant overall improvements (36.1%, p < 0.001), reductions in pain (27.2%, p < 0.001), fatigue (37.8%, p < 0.001), gastrointestinal symptoms (54.7%, p < 0.001) and improved ability to complete tasks and participate in activities (quality of life indicators) (39.1%, p < 0.001). Regression analysis of the data using a generalized mixed-effects model and calculating R2 values indicated that reductions in pain, fatigue and gastrointestinal symptoms and improvements in quality of life indicators were consistent, and occurred with a low degree of variance. Males responded slightly better to the combination supplement than females but for most parameters these differences were not significant. Conclusions: The combination membrane lipid replacement glycerolphospholipid supplement with controlled-release caffeine was safe and effective and significantly reduced pain, fatigue and gastrointestinal symptoms as well as improved QOL indicators in fibromyalgia patients.